Morbidity and Mortality of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy in Patients Aged 70 Years and Older: A Two-Center 10-Year Experience
Journal of Surgical Oncology, 2026 (SCI-Expanded, Scopus)
- Yayın Türü: Makale / Tam Makale
- Basım Tarihi: 2026
- Doi Numarası: 10.1002/jso.70393
- Dergi Adı: Journal of Surgical Oncology
- Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, EMBASE, MEDLINE, Biomedical Reference Collection: Corporate Edition (EBSCO), Health Research Premium Collection (ProQuest)
- Anahtar Kelimeler: cytoreductive surgery, elderly, hyperthermic intraperitoneal chemotherapy, morbidity, mortality, peritoneal carcinomatosis, surgical outcomes
- Sağlık Bilimleri Üniversitesi Adresli: Evet
Özet
Background and Objectives: Cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) is established for peritoneal surface malignancies, but its use in older patients is debated. We assessed CRS-HIPEC morbidity and mortality in patients aged ≥ 70 years using a cohort of younger patients as a comparator. Methods: We retrospectively reviewed consecutive patients aged ≥ 70 and < 70 undergoing CRS-HIPEC for peritoneal carcinomatosis at two centers (2017−2026). Peritoneal carcinomatosis index (PCI), completeness of cytoreduction (CC), complications (Clavien-Dindo), and mortality were analyzed. Results: Ninety-five patients were included (53 female; mean age 74.7 years; 10 [10.5%] aged ≥ 80; 70 [73.7%] ASA III−IV). Commonest primaries: colorectal (40), gastric (14), ovarian (12). Mean PCI was 15.6; complete cytoreduction (CC-0) was achieved in 58.9%. Complications were Clavien-Dindo grade III−IV in 11.6%, and grade V in 3.2%; major morbidity (≥ III) was 14.7%. Longer operative time (p = 0.013) and intraoperative transfusion (p = 0.027) were associated with major morbidity in the elderly cohort, whereas age was not (p = 0.161). Overall mortality was 12/95 (12.6%). Conclusions: In selected patients aged ≥ 70 years, CRS-HIPEC achieved morbidity and mortality comparable to the younger group, with most complications low-grade. Advanced age alone should not preclude CRS-HIPEC; candidacy depends on comorbidity, performance status, and the likelihood of complete cytoreduction.